Peer-reviewed veterinary case report
Trilostane low vs high dose for small dogs with Cushing's disease
By Cho, K-D et al.·Published in Journal of veterinary internal medicine·2013·Chungbuk National University, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
- Species:
- dog
Plain-English summary
A group of small dogs weighing less than 5 kg with pituitary-dependent hyperadrenocorticism (a condition causing excessive cortisol) were treated with either low-dose or high-dose trilostane. The dogs receiving the low dose showed improvement, but it took longer compared to those on the high dose. However, some dogs on the high dose developed concerning side effects. By the end of the study, all dogs in both groups showed improvement in their symptoms, suggesting that the low-dose trilostane given twice daily is a safe and effective treatment option for this condition.
People also search for: dog Cushing's disease treatment · small dog trilostane dosage · pituitary-dependent hyperadrenocorticism symptoms
Abstract
BACKGROUND: Trilostane is commonly used to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs. There are differing opinions regarding the dose and frequency of trilostane administration in dogs with PDH. OBJECTIVES: To compare the efficacy of 2 trilostane protocols in the treatment of dogs with PDH. ANIMALS: Sixteen client-owned dogs with PDH and a body weight <5 kg. METHODS: Prospective observational study. Group A (n=9; low-dose treatment group) received 0.78 ± 0.26 mg of trilostane/kg PO every 12 h and group B (n = 7; high-dose treatment group) 30 mg of trilostane/dog PO every 24 h. All of the dogs were reassessed at 2, 4, 8, 12, 16, and 24 weeks after the initiation of treatment. RESULTS: An improvement in both ACTH-stimulated serum cortisol concentrations and clinical signs occurred more slowly in group A than in group B; however, after 20 weeks of treatment, 2/7 dog in group B had clinical signs and abnormal laboratory findings consistent with hypoadrenocorticism. At 24 weeks, an improvement in the clinical findings of all of the dogs in both groups was detected. CONCLUSIONS AND CLINICAL IMPORTANCE: In dogs with PDH, twice-daily administration of low-dose trilostane is an effective approach to the management of PDH. In addition, our results suggest fewer potential adverse effects if trilostane is administered twice daily in the lower dose.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23167780/